Navigation Links
AACE Issues New Medical Guidelines for Proper and Ethical Use of Growth Hormone
Date:11/3/2009

JACKSONVILLE, Fla., Nov. 3 /PRNewswire-USNewswire/ -- Today the American Association of Clinical Endocrinologists (AACE) released new medical guidelines for the accurate diagnosis and effective ethical treatment of growth hormone deficiency in affected patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b)

Growth hormone replacement therapy has proven useful for children and adults with scientifically proven growth hormone deficiency. In recent years, however, growth hormone use for anti-aging and athletic enhancement has increased to the point that this use currently accounts for approximately 30 percent of growth hormone prescriptions in the United States (1). A number of professional athletes have now admitted or have been alleged to have used HGH to speed recovery from injury or to enhance performance. Anti-aging centers tout benefits of HGH to slow the aging process.

"Although there is not a wealth of medical data published concerning HGH as a recovery tool for injured athletes, it's certainly not an approved indication for use," Dr. David Cook, Interim Division Chief of Endocrinology at the Oregon Health & Science University, and co-author of the new medical guidelines said.

In addition to addressing the increasing misuse of growth hormone in anti-aging and sports, the AACE guidelines more importantly address the accurate diagnosis and effective therapy for growth hormone deficient patients, as well as new cut points or benchmarks for growth hormone testing.

"These guidelines are the result of recent advancements in our understanding of the benefits of growth hormone replacement for patients," Dr. Cook said.

Responsiveness to growth hormone therapy is often determined by many variables, such as age, sex, adiposity, and concurrent medications. However, even after accounting for these variables, there remain highly individual differences in the response to growth hormone.

"Controlled trials, using strict dosing regimes and measuring clinical end points, such as body composition and insulin sensitivity, have shown us that growth hormone dosing should be individualized, with close attention to avoiding side effects," Dr. Cook said.

The AACE guidelines also outline new cut points for stimulation testing of growth hormone deficiency. Stimulation testing measures normal secretion or low growth hormone secretion, making them an accurate barometer to gauge growth hormone deficiency.

"If the cut point is five and the highest response is four, then the patient is growth hormone deficient," Dr. Cook said. "Some tests also depend upon body mass index such as the Arginine + growth hormone releasing hormone stimulation test."

Despite a growing body of evidence on the benefits of growth hormone therapy, there is still considerable inconsistency in the United States in the clinical practice of growth hormone replacement for adults.

"There are multiple factors accounting for this," Dr. Cook said. "Such as the high cost of growth hormone therapy, the need for daily injections, the lack of awareness regarding its indications, diagnosis, long-term surveillance, and concerns about whether there are long-term risks involved."

Consequences of untreated growth hormone deficiency include cardiovascular complications, metabolic complications, osteopenia/osteoporosis, and diminished quality of life.

To view the AACE guidelines, please Click Here.

About AACE

AACE is a professional medical organization with more than 6,000 members in the United States and 92 other countries. Founded in 1991, AACE is dedicated to the optimal care of patients with endocrine problems. AACE initiatives inform the public about endocrine disorders. AACE also conducts continuing education programs for clinical endocrinologists, physicians whose advanced, specialized training enables them to be experts in the care of endocrine disease, such as diabetes, thyroid disorders, growth hormone deficiency, osteoporosis, cholesterol disorders, hypertension and obesity.

About the American College of Endocrinology (ACE)

The American College of Endocrinology (ACE) is the educational and scientific arm of the American Association of Clinical Endocrinologists (AACE). ACE is a scientific and charitable medical organization dedicated to promoting the art and science of clinical endocrinology for the improvement of patient care and public health. The American College of Endocrinology is the leader in advancing the care and prevention of endocrine and metabolic disorders by: providing professional education and reliable public health information; recognizing excellence in education, research and service; promoting clinical research; and defining the future of clinical endocrinology.

About Endocrine Practice

Endocrine Practice is the official scientific publication of the ACE and the AACE. It publishes the latest information in the treatment of diabetes, thyroid disease, obesity, growth hormone deficiency, sexual dysfunction, and osteoporosis, among others. The journal contains original articles, case reports, review articles, AACE Medical Guidelines for Clinical Practice, commentaries, editorials, and visual images. The total circulation of Endocrine Practice exceeds 5,300. Of these readers, 94 percent are physicians who treat endocrine-related disorders. Readership includes subscriptions in 84 countries, as well as many medical schools and research facilities.

(1) Lyle WG. Human growth hormone and anti-aging. Plast Reconstr Surg. 2002;110:1585-1589.

SOURCE American Association of Clinical Endocrinologists


'/>"/>
SOURCE American Association of Clinical Endocrinologists
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Impact of Counterfeits on Parallel Trade & Pharmaceutical Distribution: Issues, initiatives and insights for supply chain integrity
2. China National Medicines Corporation Issues Milestone Purchase Order for 12,000 STA Systems
3. FDA Issues Another Emergency Use Authorization for Commercial H1N1 Flu Test to Quest Diagnostics Focus Diagnostics
4. Unomedical Issues Worldwide Recall of Certain Manual Pulmonary Resuscitators
5. FDA Issues Complete Response Letter for Carisbamate
6. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
7. Society of Gynecologic Oncologists Issues White Paper on HPV Vaccines Impact on Cervical Cancer Prevention
8. Pennsylvania Agriculture Department Issues Quarantine for Allegheny County Horse Stable
9. FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents
10. Avon Protection Systems Issues Correction/Clarification on ST53 SCBA System
11. Pharmos Issues Business Update on Dextofisopam Trial and Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):